5,000 patients later Roche scraps its TIGIT
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
Reblozyl flops in a new anaemia use
The Bristol/Merck’s drug’s hopes in myelofibrosis have taken a blow.
How MiNK stole the NK T show
A single but durable stable disease sends the microcap's stock up 730%.
Early validation for in vivo Car-T
ESO-T01 delivers its first four multiple myeloma case reports.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
